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Abstract
Objective—To review the safety and pharmacokinetics of antibiotics recommended for anthrax 
post-exposure prophylaxis and treatment in pregnant women.
Data Sources—Articles were identified in the PUBMED database from inception through 
December 2012 by searching the keywords ([“pregnancy]” and [generic antibiotic name]). 
Additionally, hand searches of references from REPROTOX, TERIS, review articles and Briggs’ 
Drugs in Pregnancy and Lactation were performed.
Methods of Study Selection—Articles included in the review contain primary data related to 
the safety and pharmacokinetics among pregnant women of five antibiotics recommended for 
anthrax post-exposure prophylaxis and treatment (ciprofloxacin, levofloxacin, moxifloxacin, 
doxycycline, amoxicillin), and of nine additional antibiotics recommended as part of the treatment 
regimen (penicillin, ampicillin, linezolid, clindamycin, meropenem, doripenem, rifampin, 
chloramphenicol, or vancomycin).
Tabulation, Integration and Results—The PUBMED search identified 3850 articles for 
review. Reference hand searching yielded nine additional articles. In total, 112 articles met the 
inclusion criteria.
Conclusions—Overall, safety and pharmacokinetic information is limited for these antibiotics. 
Although small increases in risks for certain anomalies have been observed with some antibiotics 
recommended for prophylaxis and treatment of anthrax, the absolute risk of these antibiotics 
appears low. Given the high morbidity and mortality associated with anthrax, antibiotics should be 
dosed appropriately to ensure that antibiotic levels can be achieved and sustained. Dosing 
adjustments may be necessary for the beta lactam antibiotics and the fluoroquinolones to achieve 
therapeutic levels in pregnant women. Data indicate that the beta lactam antibiotics, the 
fluoroquinolones, and, to a lesser extent, clindamycin enter the fetal compartment, an important 
consideration in the treatment of anthrax, as these antibiotics may provide additional fetal benefit 
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in the 2nd and 3rd trimesters of pregnancy. Additional well designed safety and pharmacokinetic 
studies are needed.
Introduction
During the 2001 anthrax attacks, approximately 10,000 people were offered antibiotic 
prophylaxis after potential exposure to B. anthracis spores in contaminated mail, including 
many pregnant women.1 Following this intentional release of anthrax, the Centers for 
Disease Control and Prevention (CDC) and the American College of Obstetricians and 
Gynecologists (ACOG) issued clinical guidance for anthrax post-exposure prophylaxis and 
treatment during pregnancy.2, 3 Anthrax remains a national concern4–6 and was recently 
described as “one of the most serious threats to national security and the health of the 
nation”.5 As such, the CDC is updating antibiotic post-exposure prophylaxis (PEP) and 
treatment guidance for anthrax, including recommendations specific to pregnant women, 
and review of safety and pharmacokinetic data provides an evidence-base for these 
recommendations.
B. anthracis manifests in three main forms of infection, cutaneous, gastrointestinal and 
inhalation,7 and is a highly lethal infection with historical mortality rates as high as 88% for 
the inhalational form.8 In the bioterrorist event in 2001, exposure to spores resulted in 
cutaneous and inhalational forms, and despite aggressive treatment, non-pregnant adults 
with inhalation anthrax experienced a 45% mortality rate.9 A historical analysis of published 
anthrax cases in pregnant women confirmed that this infection can result in maternal death 
and fetal deaths.10 Taken together, these data suggest pregnant women are at-risk for 
morbidity and mortality if infected with B. anthracis and highlight the importance of post-
exposure prophylaxis and treatment of anthrax in pregnant women.
Post-exposure prophylaxis for non-pregnant adults potentially exposed to B. anthracis 
spores involves antibiotic therapy for sixty days in combination with 3 doses of the U.S.-
licensed anthrax vaccine given at 0, 2, and 4 weeks. This PEP regimen is intended to prevent 
inhalation anthrax by killing bacteria as they germinate from the spore form to the active 
vegetative bacteria.11, 12 Oral ciprofloxacin, levofloxacin, moxifloxacin, doxycycline or 
amoxicillin (assuming a susceptible strain) are recommended for PEP in the general 
population;12 however, their long-term use during pregnancy raises questions about fetal 
safety. Among the antibiotics recommended for PEP, fluoroquinolones and doxycycline are 
typically avoided during pregnancy due to fetal safety concerns; avoidance of 
fluoroquinolones is based on studies demonstrating cartilage damage in young beagle dogs 
receiving postnatal treatment,13, 14 and doxycycline avoidance is based on concerns of 
dental staining seen with the tetracyclines use during pregnancy, and of fetal bone growth 
delays and skeletal anomalies, which have been reported in animal studies.15–18
Intravenous multidrug therapy with three antibiotics is recommended for the treatment of 
inhalation or severe anthrax, and nine additional antibiotics (penicillin, ampicillin, linezolid, 
clindamycin, meropenem, doripenem, rifampin, chloramphenicol or vancomycin) have been 
suggested as part of the treatment regimen.12, 19 Among these recommended antibiotics, 
fetal safety concerns have been raised with rifampin and chloramphenicol.20, 21 Rifampin 
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has been associated with growth retardation, spina bifida and cleft palate in pregnant animal 
studies.20 In addition, rifampin induces the p450 enzymatic pathway and can accelerate the 
degradation of Vitamin K, which raises concerns about neonatal bleeding with prenatal 
exposure.20 Chloramphenicol has been associated with fetal anomalies, delayed fetal growth 
and fetal death in animal studies,21 and “Grey Baby Syndrome”, cardiovascular collapse due 
to chloramphenicol toxicity, has been reported in neonates, including in one neonate with 
both in utero and post-natal exposure.21, 22
Safety concerns are not the only consideration when recommending antimicrobial 
prophylaxis and treatment for anthrax in pregnant women. The pharmacokinetics of these 
antibiotics may differ during pregnancy.23–26 To ensure appropriate dosing, physiologic 
changes that influence drug absorption and clearance need to be taken into account when 
selecting antibiotics for prenatal use.
In accordance with MOOSE guidelines, we conducted a systematic review of the safety and 
pharmacokinetic data of the 14 antibiotics most recently recommended by CDC for anthrax 
prophylaxis and treatment.11,12, 19 The goals of this systematic review are to address the 
following questions:
1. What are the risks of congenital anomalies and neonatal complications with 
pregnancy-related exposure to these antimicrobials?
2. What is known about the pharmacokinetics of these antibiotics in pregnant women 
and how does this influence dosing recommendations?
Sources
A search strategy was developed in conjunction with an expert CDC librarian. Articles were 
identified through the PUBMED database from inception until December 2012 by searching 
the keywords (“pregnancy” and [generic antibiotic name]), and limited to articles published 
in English in humans. We also hand searched REPRORISK and TERIS, electronic resources 
that summarize the safety of medications during pregnancy, and references from antibiotic 
review articles.14, 27, 28 We reviewed the Food and Drug Administration Pregnancy 
Category ratings for each antibiotic; a description of these ratings is available at http;//
accessdata.fda.gov/scripts/cder/drugsatfda. Lastly, we hand searched the references included 
in the specific antibiotic sections of the textbook, Briggs’ Drugs in Pregnancy and Lactation, 
a commonly cited practical reference obstetricians use when evaluating medication risks in 
pregnancy.29
Study Selection
For inclusion, articles needed to: 1) contain peer-reviewed primary data related to the use of 
antibiotics recommended by CDC (ciprofloxacin, levofloxacin, moxifloxacin, doxycycline, 
amoxicillin, penicillin, ampicillin, linezolid, clindamycin, meropenem, doripenem, rifampin, 
chloramphenicol, vancomycin) for anthrax prophylaxis and treatment, and 2) describe safety 
during pregnancy (restricted to articles with 5 or more cases) or contain pharmacokinetic 
data during pregnancy (no restriction on the number of cases). Unpublished reports, 
abstracts, duplicate reports, policy guidelines and review articles were excluded from the 
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review because they did not contain primary data. However, these articles were used to 
identify additional primary references. No restriction was placed on the timing in gestation 
of antibiotic administration for article inclusion; early pregnancy exposure was reported with 
respect to anomalies. Articles describing treatment of preterm labor, preterm premature 
rupture of membranes, and premature rupture of membranes were excluded due to the late 
antibiotic exposure and the confounding factors contributed by these conditions. Similarly, 
studies related to the treatment of syphilis were excluded because syphilis-related adverse 
neonatal outcomes would complicate study interpretation.
One reviewer (DMD) screened all titles and relevant abstracts identified through PUBMED 
and the hand searches, and selected articles for full-text review that contained primary 
clinical data involving each of the specific antibiotics used during pregnancy. Case series, 
case-control studies and prospective and retrospective cohort studies were included. A 
second reviewer (DJJ) independently extracted data from 20% of the articles, with 100% 
concordance between the two reviewers. Experts in obstetrics, anthrax, emerging infectious 
diseases, emergency preparedness, birth defects, and pediatrics reviewed the manuscript and 
the cited references to ensure accuracy and completeness.
Results
The PUBMED database search identified 3850 articles and the additional hand searches of 
review articles, REPRORISK and TERIS databases (periodically updated online database 
maintained by Thomson Reuters Micromedex Solutions) and relevant references in the 
textbook Briggs’ Drugs in Pregnancy and Lactation revealed 9 articles. Overall, 112 papers 
were included in this review (Tables I and II).
Ciprofloxacin
Nine studies (1100 exposed women) described ciprofloxacin use in pregnancy.30–39 In the 
largest prospective study of 549 quinolone-exposed pregnancies, no increased risk for 
adverse obstetrical outcomes was observed, and the malformation rate among 390 live-born 
infants exposed to fluoroquinolones during the first trimester of pregnancy (4.9%) was 
similar to previously reported malformation rates. Among these were 70 ciprofloxacin-
exposed infants, of which 2 (4%) were reported as malformed.32 Additionally, this report 
included prospective and retrospective data reported to the manufacturer’s registry and other 
databases. Although no unexposed comparison group was included, six live-born infants 
with major or minor malformations were reported among 116 pregnancies with prenatal 
fluoroquinolone exposure, well within the expected rate of major and minor 
malformations.4032 Also included in this report were 25 retrospective cases of malformed 
children with prenatal fluoroquinolone exposure, eight of whom were exposed to 
ciprofloxacin.32 Given the lack of an unexposed comparison group and the inclusion of 
minor malformations, the interpretation of these results is difficult.32 Nevertheless, when 
combined, the reported data from these 690 pregnancies did not detect a specific pattern of 
anomalies with ciprofloxacin or with any prenatal fluoroquinolone exposure.32 In seven 
additional studies, no specific pattern of birth defects was reported in association with 
ciprofloxacin use.31, 33–39, 41 Among a small database cohort of 130 women who filled a 
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fluoroquinolone prescription during the first trimester of pregnancy or 30 days before 
conception, 4 children with anomalies (2 with exposure to ciprofloxacin) were reported; 
however, rates of congenital malformations among infants born to exposed (3.1%) and 
unexposed (4.2%) women were similar (Prevalence Rate=0.7, 95% Confidence Interval (CI) 
0.3–2.0).38 No increased risk of stillbirth, perinatal death, preterm delivery or low birth 
weight was observed in that study.38 Cooper et al., in their largest retrospective cohort study 
of 24,521 infants with fetal antibiotic exposure compared to 3400 infants without exposure, 
included 588 infants exposed to ciprofloxacin during pregnancy. Ciprofloxacin exposure 
anytime during pregnancy was not associated with malformations (Relative Risk (RR)=0.97, 
95% (CI) 0.58–1.36), nor was exposure in early pregnancy (n=439, RR=0.64, 95% CI 0.31–
1.3).31 Three studies of prenatal exposure to ciprofloxacin did not observe an association 
with developmental delays, musculoskeletal dysfunction.33, 37, 41
Few investigations have directly assessed the pharmacokinetics of quinolones during 
pregnancy. (Table III) Serum drug levels of ciprofloxacin among 40 pregnant women were 
lower than among non-pregnant women (0.18 µg/ml vs. 1.06 µg//ml 4 hours post 
administration; 0.09 µg//ml vs. 0.54 µg//ml 6 hours post administration).42 Ciprofloxacin 
crosses the placenta, with amniotic fluid concentrations increasing over time.42 Consistent 
with this, an ex-vivo experimental system using human placental tissue demonstrated 
placental perfusion and detectable ciprofloxacin drug levels in the fetal compartment.43
Levofloxacin
No studies evaluating the safety of levofloxacin in pregnancy were identified. Two 
investigations of the in-vivo maternal pharmacokinetics of levofloxacin found that 
levofloxacin crossed the placenta and produced fetal levels approximately 66% of maternal 
levels <1 hour after dosing (5.44 µg/ml vs. 8.18 µg/ml).44, 45 Similar to ciprofloxacin, ex-
vivo placental perfusion models demonstrated transplacental transfer of levofloxacin but at 
lower rates than in vivo studies.43
Moxifloxacin
No studies evaluating the safety of moxifloxacin in pregnancy were identified. Moxifloxacin 
has been demonstrated in umbilical cord blood and amniotic fluid after maternal 
administration.44, 46 Maternal pharmacokinetics of moxifloxacin found that moxifloxacin 
crossed the placenta and produced fetal levels approximately 90% of maternal levels <1 
hour after dosing (3.57 µg/ml vs. 4.96 µg/ml). Additionally, comparison of moxifloxacin 
plasma levels between postpartum and non-pregnant women after a single intravenous dose 
demonstrated lower peak serum concentrations and higher volume of distribution among the 
postpartum women (1.96 µg/ml vs 4.95 µg/ml.)47
Doxycycline
We identified five articles (2164 exposed pregnant women) on the safety of doxycycline in 
pregnancy.31, 48–50 The largest of these, the retrospective cohort by Cooper et al., included 
1843 exposures during pregnancy, and reported similar rates of congenital anomalies among 
infants born to doxycycline-exposed and unexposed women, in the first 4 months of 
pregnancy (n=1691, RR=0.85, 95% CI 0.59–1.23) or anytime during the pregnancy 
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(RR=0.84, 95% CI 0.59–1.19)31 An elevated relative risk of 2.96 (95% CI 0.75–11.67) was 
reported for orofacial clefts with doxycycline use in the 1st four lunar months, but this 
increase was not statistically significant. In a case-control study, 56 (0.30%) of 18,515 
infants with congenital anomalies were exposed to doxycycline compared to 63 (0.19%) of 
32,804 control infants (p=0.01). Using case-matched control paired analysis, a marginally 
statistically significant association (Odd Ratio [OR] =1.6, 95% CI 1.0–2.4) was reported 
with doxycycline exposure during pregnancy and congenital abnormalities. However, 
exposure in the 2nd and 3rd gestational month, the period of embryogenesis, was not 
significantly associated with anomalies (OR =1.8, 95% CI 0.7–5.0).48 In a cohort study of 
maternal antibiotics and orofacial clefts, 2 cases of doxycycline/tetracycline exposure in the 
2nd month of gestation, suggested an increased risk of cleft lip with/without cleft palate (CL
+/−CP), (POR=7.30, 95% CI 1.81–29.46); however the risk estimate was no longer 
statistically significant when the exposure interval was extended to 3 cases exposed in the 
1st trimester.51 In the National Birth Defects Prevention Study, the adjusted odds ratio 
(AOR) for all oral clefts associated with periconceptional and early pregnancy exposure to 
tetracyclines was not significant (AOR=2.0,95% CI 0.6–6.7).52 In a small prospective cohort 
study (n=34), no anomalies were reported in association with doxycycline exposure at one 
year of follow up.50 Regarding pharmacokinetics, the only study that we identified 
demonstrated that systemic drug concentrations among women during the second trimester 
were similar to those in non-pregnant subjects.53
Amoxicillin
We identified fourteen studies (15,917 exposed pregnant women) on the safety of 
amoxicillin during pregnancy.30, 31, 36, 54–62 The large retrospective cohort by Cooper et al, 
included 14,534 amoxicillin-exposures, which showed no increased risk of major congenital 
anomalies, with exposure during the 1st four lunar months (RR=1.09, 95% CI 0.86–1.37) or 
any time during pregnancy (RR=0.99, 95% CI 0.80–1.23). A non-statistically significant 
increased risk of orofacial clefts (RR=1.67, 95% CI 0.56–5.04) was observed with 
amoxicillin exposure in the 1st 4 lunar months of pregnancy.31 Findings from six smaller 
studies did not confirm an increased risk of defects.36, 56, 57, 59–61 A recent case-control 
study of 877 case infants with CL+/−CP found a higher rate of first trimester amoxicillin-
exposure among mothers of case-infants (n=28) than among mothers of control-infants 
(OR=2.0, 95% CI 1.0–4.1).54 A similar finding was seen in an earlier case-control study 
(n=1374 cases); a statistically significant association between amoxicillin exposure and CL
+/−CP (n=7) was observed. The prevalence odds ratios were 15.9 (95% CI 4.9–51.2) when 
compared to population controls and 5.4 (95% CI 1.9–15.4) when compared to malformed 
controls.55 However, a recent large cohort study (n=806,011) found that maternal antibiotic 
exposure early in pregnancy was not associated with an increased risk of CL+/−CP 
(POR=1.08; 95% CI 0.89–1.30).51 In that study, only 9 cases were exposed to amoxicillin in 
the 1st trimester of pregnancy and overall none of the penicillins were associated with an 
increased risk.51 No evidence of an increased risk of congenital anomalies was seen in four 
other studies of amoxicillin plus clavulanate use during critical time periods.30, 58, 61, 63
In a study in which a single oral dose of amoxicillin was given to pregnant women,23 renal 
clearance and secretion were significantly higher during pregnancy than during the 
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postpartum period. Amoxicillin had a shorter half-life (by ~25%) during pregnancy when 
compared to postpartum controls. Moreover, area under the concentration time curves and 
peak concentration were significantly lower during pregnancy.23 An investigation of oral 
absorption and subsequent systemic amoxicillin levels found similar results.64 In contrast, 
studies of intravenous amoxicillin during pregnancy and/or labor found similar systemic 
levels as seen in non-pregnant subjects.65, 66 Regarding transplacental passage, intravenous 
maternal amoxicillin used to prevent neonatal group B streptococcus (GBS) infection 
crossed the placenta at levels presumed to be adequate to prevent the infection.66
Penicillin
We identified eight studies (a total of 1685 exposed pregnancies) of the association between 
prenatal penicillin exposure and congenital anomalies among infants.52, 55, 63, 67–71 Overall, 
no specific pattern of anomalies was detected. Some small studies reported increases in 
isolated birth defects, but no specific defects were consistently reported.52, 55, 67–71
We reviewed seven pharmacokinetic studies of penicillin use in pregnancy72–78 which 
demonstrated rapid transplacental penicillin passage as early as 10 weeks gestation.74 
Amniotic fluid concentrations were comparable to maternal serum levels78 and were 
considered sufficient to inhibit penicillin-sensitive bacteria.72, 73, 75, 78 Based on renal 
elimination rates of penicillin in the 3rd trimester, a four-hour dosing interval is considered 
optimal to achieve adequate amniotic fluid levels that will inhibit penicillin-sensitive 
bacteria.72
Ampicillin
We identified 11 studies (with data on 7658 exposed pregnancies) on the association 
between prenatal ampicillin exposure and congenital anomalies.36, 55, 69, 79–84 A case-
control study involving 390 infants with congenital heart disease demonstrated an 
association between prenatal ampicillin use and congenital heart disease with a prevalence 
ratio estimate of 3.3 (90% CI 1.3–8.1), however, it was based on only 14 cases and controls 
(7 in each group) that were exposed during pregnancy.81 In contrast, a subsequent case-
control study of 298 children with congenital heart disease did not identify this association 
with ampicillin exposure during the 1st trimester (prevalence OR=1.2, 95% CI 0.58–2.3).84 
Similarly, a large population-based case-control study of 1644 women prenatally exposed to 
ampicillin found the rate of malformed newborns exposed to ampicillin (7.2%) was 
comparable to controls (6.9%), and no increased risk of cardiovascular anomalies was 
reported.79, 82 Instead, cleft palate (CP) (OR=2.5, 95% CI 1.1–5.4), syndactyly (OR=2.4, 
95% CI 1.2–4.8), and abdominal wall defects (OR=15.2, 95% CI 1.1–127.8) were seen more 
frequently among infants whose mothers had 1st trimester ampicillin exposure.79, 82 When 
the time period for exposure to ampicillin was restricted to the critical period of 
organogenesis for each of these defects, the risk for abdominal defects was no longer 
statistically significant (OR=13.0, 95% CI=0.7–230.8).82 In contrast, a large cohort study 
(n=806,011) evaluated maternal antibiotic exposure early in pregnancy and reported no 
increased risk of CP (POR=1.14;95% CI 0.86–1.51).51 First trimester ampicillin or 
pivampicillin (an ester of ampicillin used to increase oral bioavailability) was observed in 
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only three cases of CP.51 Although isolated minor defects were observed in smaller studies, 
no specific pattern was seen.36, 55, 63, 69, 80, 81, 83, 84
Increased elimination, shortened serum half-life and increased total body clearance of 
ampicillin has been seen in pregnant women, compared to non-pregnant women.85 The 
mean peripheral volume of distribution was twice as large as that of non-pregnant adults, 
and mean plasma levels of ampicillin were ~50% lower during pregnancy.25, 86–88 We 
identified 19 studies73, 87–103 all of which confirmed transplacental ampicillin passage, 
resulting in levels in the fetal circulation deemed adequate to prevent and treat susceptible 
infections73, 89–105
Linezolid
We identified no articles on the safety or pharmacokinetics of linezolid during pregnancy.
Clindamycin
We identified one randomized controlled study of 276 women given prenatal clindamycin 
for six weeks in the 2nd and 3rd trimester, as treatment for genital mycoplasma to prevent 
low birth weight. Similar rates of malformations were reported among exposed (3.9%) and 
unexposed infants (4.4%), and no differences in birth weight were detected.106 Maternal 
administration of clindamycin, based on non-pregnant doses resulted in serum 
concentrations similar to previously reported levels in male subjects107 and in non-pregnant 
women.108 Pharmacokinetic studies demonstrated transplacental passage of 
clindamycin,107, 109–112 and when multiple doses were used, clindamycin and its bioactive 
metabolites were demonstrated in the amniotic fluid and in fetal tissues.111 However, the 
distribution of clindamycin into the fetal compartment appears decreased by increased 
protein binding, which may be increased during pregnancies complicated by infection.109
Meropenem
We identified no articles on the safety of meropenem during pregnancy. Pharmacokinetic 
data were limited to a single ex-vivo human placenta perfusion model that demonstrated 
transplacental passage, with dose-dependent levels in the fetus that were lower than maternal 
serum levels. Based on these limited data, these levels were considered subtherapeutic to 
treat many fetal infections.113
Doripenem
We identified no articles on the safety or pharmacokinetics of doripenem during pregnancy.
Rifampin
We identified nine articles on the safety of prenatal exposure to rifampin (332 women on 
rifampin alone or in combination with other antimicrobial agents).114–122 No specific pattern 
of congenital anomalies was observed, and most outcomes were healthy pregnancies. In the 
largest case series of rifampin use among 226 pregnant women, nine children were noted to 
have major or minor congenital anomalies, but no specific pattern was reported.123 Ten 
rifampin-exposed newborns were reported to have “hemorrhagic tendencies” but no further 
clinical information was provided.123 Based on one case report, rifampin crossed the 
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placenta and was measurable in the amniotic fluid and in fetal tissue124; no additional 
pharmacokinetic data are available.
Chloramphenicol
We found five studies (totaling 290 pregnant women) with prenatal chloramphenicol 
exposure.67, 125–128 Data from these five observational studies, did not suggest an increased 
risk of birth defects with maternal chloramphenicol use.67, 125–127 Chloramphenicol crosses 
the placenta producing cord blood levels 30–106% of maternal levels.129, 130
Vancomycin
We identified two studies of the safety of vancomycin during the 2nd and 3rd trimester of 
pregnancy (with data on 23 pregnancies).131, 132 Data are not available on the incidence of 
birth defects with maternal use of vancomycin, but other neonatal toxicities were evaluated 
in these studies. Because renal and ototoxicity are a concern with the vancomycin use, ten 
neonates exposed in utero were evaluated post-delivery; no defects were demonstrated.132 
Apgar scores were normal in neonates exposed to vancomycin at the time of cesearean 
delivery.131 Vancomycin readily crosses the placenta131–136 and enters the amniotic fluid 
and cord blood. In two studies, increased vancomycin doses were needed during pregnancy 
to achieve therapeutic serum levels132, 134 but another study found that despite increased 
volume of distribution and plasma clearance, vancomycin levels remained in the therapeutic 
range during pregnancy without dosage adjustment.135
Discussion
This review summarizes safety and pharmacokinetic data during pregnancy for 14 
antibiotics recommended for prophylaxis and treatment of anthrax. Pre-event analysis of the 
safety and pharmacokinetics of these antibiotics informs national guidelines and provides 
women and their health care providers with needed information, possibly resulting in 
improved adherence to public health recommendations during an anthrax event.
Ciprofloxacin and doxycycline are first-line antibiotics for anthrax post-exposure 
prophylaxis for adults. Levofloxacin and moxifloxacin are alternative fluoroquinolones if 
ciprofloxacin is not tolerated or unavailable. Amoxicillin may also be used as prophylaxis 
against susceptible strains of anthrax. Fluoroquinolones are generally avoided during 
pregnancy due to concerns about potential effects on developing cartilage, based on animal 
studies.13, 14, 137, 138 Our review identified no human studies that validated these concerns; 
instead, available data suggest it is unlikely that ciprofloxacin poses substantial fetal safety 
risks. Appropriate dosing of fluoroquinolones in pregnant women is not clear; limited 
pharmacokinetic data suggest that these renally-excreted drugs may require higher or more 
frequent dosing.42, 47
Doxycycline is also generally avoided during pregnancy due to concerns about dental 
staining, fetal growth delays and maternal hepatic toxicity,15, 16, 18, 27, 139–141 concerns 
based on experience with prenatal tetracycline use and animal studies. In studies of prenatal 
doxycycline use, no neonates demonstrated dental staining or growth delays and no maternal 
hepatic toxicity was reported among mothers, suggesting that these risks are likely to be 
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low. Although not consistently demonstrated, this review does raise the question of the 
potential risk for orofacial clefts with the use of doxycycline. However, it is difficult to 
disentangle the effects of antibiotic treatment from the effects of the underlying infection; 
maternal febrile illness has been associated with orofacial clefts CL+/−CP as well as with 
other congenital abnormalities.142143, 144 Infections, such as influenza-like illness, have also 
been reported in association with congenital anomalies.145 Based on the low birth 
prevalence of orofacial clefts (11/10,000 livebirths), and the potential confounder of 
maternal febrile illness, the absolute risk oforofacial clefting with doxycycline exposure is 
likely to be low.
More data are needed to guide dosing for pregnant women, but the very limited data 
available suggest that dosing adjustments may not be necessary during pregnancy.53 
Doxycycline undergoes both hepatic and renal excretion; while these excretion mechanisms 
might impact doxycycline levels during pregnancy, the effects are likely to be less than for 
the fluoroquinolones.
Although recent reports indicate a possible association of amoxicillin with facial clefts,54, 55 
some of these results reach only borderline statistical significance.54 In addition, if we 
assume a doubling of the risk54 in the context of the estimated birth prevalence for CL+/
−CP146, the absolute risk of orofacial clefts with exposure to amoxicillin would still be 
considered low. A large case-control study, the National Birth Defects Prevention Study, did 
not demonstrated an increased risk of orofacial clefts with exposure to the penicillin drug 
class, which although not specified, likely included exposures to amoxicillin.52 In addition, 
two large retrospective cohort studies support the notion that the risk of orofacial clefts and 
amoxicillin exposure is likely low.31, 51 In terms of dosing, amoxicillin for the non-pregnant 
population may be insufficient to prevent anthrax in pregnant women,23 thus, placing these 
women at risk of sub-therapeutic drug levels and possibly the development of antibiotic 
resistance.147
The fluoroquinolones, doxycycline and amoxicillin are not only recommended for post-
exposure prophylaxis for anthrax, but, along with nine additional antimicrobials, are among 
those recommended as a component of the combination antibiotic treatment. Decisions 
regarding the administration of antibiotics for treatment of pregnant women involves 
assessing antibiotic safety and fetal risks, but also must take into account disease-related 
risks and maternal survival benefit. For the additional nine antibiotics recommended as 
possible treatment, no definitive evidence of an association of prenatal antibiotic use and 
congenital anomalies exist.
Although ampicillin was associated with isolated cleft palate in one case-control study, this 
association was not uniformly demonstrated.51, 52 Based on the estimated national birth 
prevalence for isolated cleft palate (6/10,000 births), doubling or even tripling the risk would 
still lead to a low absolute risk for this anomaly to occur after ampicillin exposure. Both 
amoxicillin and ampicillin demonstrate associations with orofacial facial anomalies, we 
believe these findings are unrelated, given the phenotypes – cleft lip with and without cleft 
palate and isolated cleft palate -are etiologically distinct.148. Although meropenem and 
doripenem have structural similarities to the ampicillin and the penicillins, we could not 
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identify any safety data for these antibiotics. We were also unable to find any published 
reports of linezolid safety or pharmacokinetics.
Theoretical concerns of “Grey Baby Syndrome” resulting from chloramphenicol use during 
pregnancy were not substantiated in this review. Given that data are available for only 290 
pregnancies, the potential for this syndrome to occur with prenatal exposure to 
chloramphenicol has not been excluded; chloramphenicol would not be a preferred antibiotic 
if other antibiotics are readily available. However, as a life-saving measure for a pregnant 
woman, particularly when meningeal involvement with anthrax is confirmed or suspected, 
chloramphenicol would not be contraindicated, given that this antimicrobial enters the 
central nervous system readily.
Maternal rifampin exposure during pregnancy was associated with newborn “hemorrhagic 
tendencies”123 in one study, yet the clinical significance of this finding is unknown. A case 
series report of 3 neonates prenatally-exposed to rifampin was not included in our review 
because it contained less than 5 cases; however, in this series three neonates demonstrated 
substantial hemorrhagic complications and consequently, two died from blood-loss related 
hypovolemic shock.118 Additionally, given that rifampin induces p450 hepatic enzymes, 
which can result in increased degradation of Vitamin K14, and is capable of crossing the 
placenta, there is biologic plausibility for an association with neonatal bleeding. Bleeding 
concerns would not be a contraindication for rifampin anthrax treatment, but it would be 
important to ensure that all infants born to mothers receiving rifampin during pregnancy 
receive prophylactic Vitamin K and be monitored closely for signs of bleeding.
Pharmacokinetic data are generally lacking to inform the dosing of many of the antibiotics 
recommended for treatment. Fluoroquinolones may require alternative dosing for pregnant 
women, but more data are needed. For doxycycline, no substantial data exist to recommend 
differential dosing. Beta-lactam antibiotics are nearly exclusively cleared by the renal 
system and renal filtration is increased during pregnancy; thus, treatment of anthrax with 
higher doses of amoxicillin, penicillin, ampicillin, and meropenem may be necessary during 
pregnancy. Data are mixed regarding vancomycin dosing during pregnancy, but monitoring 
vancomycin levels in pregnant women treated for anthrax may ensure adequate serum 
levels.
This systematic review has several limitations. The body of evidence reporting safety and 
pharmacokinetics of antibiotic use in pregnancy is substantially limited, as is the case with 
91% of drugs that are FDA licensed.149 Given the limited data, we chose to set our inclusion 
criteria broadly, as to provide as comprehensive an assessment as possible of the available 
data within the confines of our search. However, this means that often the data are from 
uncontrolled studies with mostly observational data, which may actually overestimate the 
risks due to publication bias. In addition, we also did not restrict the antibiotics regimen by 
dose or timing of exposure, which may lead to less accuracy when looking at specific 
neonatal outcomes. Because each antibiotic has unique chemical, pharmacokinetic, and 
potentially safety characteristics, we did not conduct the systematic search by antibiotic 
class; this limits the generalizability of our results to other antibiotics in the same class. 
Lastly, we limited our study to searches of PUBMED and to articles published in English, 
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which means there may be additional data that could be included in the safety and 
pharmacokinetic analysis of these drugs in pregnancy.
Despite these limitations, our review is strengthened by its congruence with a similar review 
article by Nahum et al27 as well as its agreement with the conclusions reached by the 
electronic resources REPROTOX and TERIS.14, 18, 20, 21 Similar to these resources, this 
review highlights the limited exposure and adverse event data available. Although new data 
suggests a closer evaluation of the risk of orofacial clefts and antibiotic exposure may be 
warranted, we have reached similar conclusions to previous authors- all of the antibiotics 
suggested for prophylaxis and treatment of anthrax - have evidence of low risks during 
pregnancy.27
The limited data demonstrate the urgent need for additional safety and pharmacokinetic 
research in pregnant women. Given the rarity of anthrax as a naturally-occurring infection, 
ex-vivo models and animal research studies may be required to study the safety and 
pharmacokinetics of antibiotics recommended for post-exposure prophylaxis and treatment 
during pregnancy. Use of these antibiotics for treatment of other infections may provide 
opportunities to capture additional safety and pharmacokinetic data, but is limited by the 
lack of an ongoing national system to capture these data effectively. In an anthrax 
bioterrorism event, women and their fetuses will be at risk for morbidity and mortality and 
might even be at higher risk for maternal and fetal death10, emphasizing the importance of 
substantial pre-event planning. To best inform clinical guidance, ongoing evaluation of new 
and existing evidence of the risks and benefits of proposed mitigating strategies or medical 
countermeasures are needed. Our review suggests that the 14 antibiotics recommended as 
part of anthrax post-exposure prophylaxis and treatment regimens for pregnant women 
likely pose low risk. However, dosing adjustments for pregnant women need to be 
considered, and future efforts to refine dosing are needed. We recommend that additional 
safety and pharmacokinetic studies involving this at-risk population be strongly considered 
to ensure adequate preparedness in the event of bioterrorism involving anthrax.
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Table 3


































Likely that dose adjustments in
pregnancy are necessary to maintain drug
levels equal to non-pregnant women.
However, no specific data exists and no
specific data-driven recommendations
can be made. Quinolone antibiotics have
approximately 50–70% excretion by
kidney.
Levofloxacin /Moxifloxacin
























Dose adjustments in pregnancy are likely
necessary to maintain drug levels equal to
non-pregnant women. However, no
specific data exists and thus no formal

















Does not appear that changes to dosing
are required. Undergoes enterohepatic



























not appear to be
clinically
significant
May need to consider shorter dosing
intervals and/or increased dosing when
attempting to achieve levels similar to
non-pregnant women. This appears to be
especially true for orally administered
drug. High level renal excretion noted
for all β-lactams
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